It is synthesized in the Golgi apparatus from precursors like GM3 and GD3. Key enzymes in this pathway include ST8SIA1 (GD3 synthase) and B4GALNT1 (GD2 synthase).
Chimeric or humanized antibodies like Dinutuximab and Naxitamab are FDA-approved for high-risk neuroblastoma. They work by triggering immune-mediated cell death (ADCC and CDC). gd2.zip
Linked to increased cell proliferation and invasion. It is synthesized in the Golgi apparatus from